Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 1, 2024Cancer MedicineOpen Access

Several factors that predict the outcome of large B‐cell lymphoma patients who relapse/progress after chimeric antigen receptor (CAR) T‐cell therapy can be identified before cell administration

View Full Paper
Ask AI
Bookmark
Share

Authors

AŠAlice ŠýkorováUniversity Hospital Hradec KrálovéFFFrantišek FolberMasaryk UniversityKPKamila PolgárováApple (Israel)

Discussion

Loading...

Member takes

Implication

Analysis identifies risk factors affecting outcomes post CAR T-cell therapy in large B-cell lymphoma patients, suggesting proactive management.

Key Points

  • Overall response rate after CAR T-cell therapy was 60%, indicating significant effectiveness post-treatment.
  • High lactate dehydrogenase and extranodal involvement correlated with reduced survival in large B-cell lymphoma patients.
  • Assessment of 107 patients revealed median overall survival for treated patients at 6.7 months versus 0.4 months for untreated ones, highlighting treatment importance after CAR-T failure, with significance (p < 0.001). This study provides critical insights into risk stratification for CAR-T therapy candidates, supporting the need for earlier intervention.

Cite This Study

Šýkorová et al. (2024) studied this question.

synapsesocial.com/papers/68e59d83b6db643587537dc2https://doi.org/10.1002/cam4.70138
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Early Failure of Frontline Rituximab-Containing Chemo-immunotherapy in Diffuse Large B Cell Lymphoma Does Not Predict Futility of Autologous Hematopoietic Cell Transplantation2014 · 151 citations
  2. 2CAR T cell therapy becomes CHIC: “cytokine help intensified CAR” T cells2023 · 29 citations
  3. 3Randomized Comparison of Gemcitabine, Dexamethasone, and Cisplatin Versus Dexamethasone, Cytarabine, and Cisplatin Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed and Refractory Aggressive Lymphomas: NCIC-CTG LY.122014 · 469 citations
  4. 4Glofitamab in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and ≥ 2 prior therapies: Pivotal phase II expansion results.2022 · 26 citations
  5. 5A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma2022 · 407 citations